Hemgenix continues to be given ‘conditional authorisation’. Which means the eu Medicines Agency determined that the main advantages of Hemgenix are larger than its risks, but the corporate must present extra proof after authorisation.a panel of three of medical professionals with knowledge in diagnosing and treating patients with hemophilia BTh